SCHEMBL431029

SCHEMBL431029

C[Si](C)(C)CCOCOCOCC[Si](C)(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ether SCHEMBL9988157 0.89 ALDH1A1 (0.31)
SCHEMBL6977447 0.86 HSD17B10 (0.32)
SCHEMBL15966191 0.86 ALDH1A1 (0.32)
SCHEMBL31381729 0.84
SCHEMBL430949 0.83
SCHEMBL6959390 0.82
SCHEMBL1374594 0.80
SCHEMBL4962174 0.80
SCHEMBL6959387 0.80
SCHEMBL18967926 0.80

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 646 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025053792-A1 COLLECTIVE SYNTHESIS OF PHANTOMOLIN FAMILY THROUGH TOTAL SYNTHESIS OF THE SESQUITERPENE LACTONE MOLEPHANTIN NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2025-03-13 WO claimed
WO-2024201393-A1 METHODS FOR THE SYNTHESIS OF NUCLEOSIDE ANALOGUES AND NUCLEOSIDES ANALOGUES DERIVED THEREFROM SIMON FRASER UNIVERSITY (CA) 2024-10-03 WO claimed
US-8334099-B2 Nucleic acid amplification using a reversibly modified oligonucleotide BI WANLI (US) 2012-12-18 US claimed
EP-2049689-B1 NUCLEIC ACID AMPLIFICATION USING A REVERSIBLY MODIFIED OLIGONUCLEOTIDE BI WANLI (US) 2011-12-21 EP claimed
EP-1979362-B1 NOVEL SILANE COMPOUNDS AND USE THEREOF IN ORDER TO FUNCTIONALISE SOLID MEDIA AND IMMOBILISE BIOLOGICAL MOLECULES ON SAID MEDIA COMMISSARIAT ENERGIE ATOMIQUE (FR) 2010-12-15 EP claimed
US-20100021970-A1 Nucleic Acid Amplification Using a Reversibly Modified Oligonucleotide BI WANLI 2010-01-28 US claimed
EP-2049689-A2 NUCLEIC ACID AMPLIFICATION USING A REVERSIBLY MODIFIED OLIGONUCLEOTIDE Bi, Wanli (US) 2009-04-22 EP claimed
US-20090005269-A1 Novel Silane Compounds and Their Use in Functionalizing Solid Supports and Immobilizing Biological Molecules on These Supports CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2009-01-01 US claimed
EP-1979362-A1 NOVEL SILANE COMPOUNDS AND USE THEREOF IN ORDER TO FUNCTIONALISE SOLID MEDIA AND IMMOBILISE BIOLOGICAL MOLECULES ON SAID MEDIA COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) 2008-10-15 EP claimed
WO-2008016562-A2 NUCLEIC ACID AMPLIFICATION USING A REVERSIBLY MODIFIED OLIGONUCLEOTIDE BI WANLI (US) 2008-02-07 WO claimed
WO-2007088186-A1 NOVEL SILANE COMPOUNDS AND USE THEREOF IN ORDER TO FUNCTIONALISE SOLID MEDIA AND IMMOBILISE BIOLOGICAL MOLECULES ON SAID MEDIA COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) 2007-08-09 WO claimed
EP-0600161-A1 Amino acid terminated polyesters having predetermined monomeric sequence United States Surgical Corporation (US) 1994-06-08 EP claimed
EP-0579173-A2 Polyesters having predeterminated monomeric sequence United States Surgical Corporation (US) 1994-01-19 EP claimed
US-5256762-A Polyesters having predetermined monomeric sequence UNITED STATES SURGICAL CORPORATION (US) 1993-10-26 US claimed
US-5248761-A Amino acid terminated polyesters having predetermined monomeric sequence UNITED STATES SURGICAL CORPORATION (US) 1993-09-28 US claimed
EP-3494996-B1 ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS AGENSYS INC (US) 2026-04-15 EP disclosed
US-12551570-B2 Compounds comprising cleavable linker and uses thereof INTOCELL, INC. (KR) 2026-02-17 US disclosed
EP-0337920-A2 Process for high regioselective esterification and ether-cleavage on unsaturated sugar compounds with the help of lipases and esterases and products obtained with that process HOECHST AKTIENGESELLSCHAFT (DE) 1989-10-18 EP disclosed
US-4792560-A ANTIALLERGENS; ANTIINFLAMMATORY AGENTS RORER PHARMACEUTICAL CORPORATION (US) 1988-12-20 US disclosed
EP-0196674-A2 Hydroxamates as modulators of arachidonic acid metabolic pathways USV PHARMACEUTICAL CORPORATION (US) 1986-10-08 EP disclosed